Boston, MA - March 4, 2026 - Diopter Technologies today announced a major clinical milestone in the development of its BioShare™ platform. In the first disease-state application of the proprietary three-layer collagen-amnion-collagen device, a patient suffering from Anterior Basement Membrane Dystrophy (ABMD) experienced a transformative improvement in visual acuity within 72 hours.

Key Clinical Findings:

• Rapid Recovery: The patient’s Best-Corrected Visual Acuity (BCVA) improved from a baseline of 20/400 (legal blindness) to 20/70 just 48 hours after application.
• Significant Gain: This represents a 7.5-line improvement on the Snellen chart, far exceeding the 3-line threshold typically considered clinically significant in ophthalmic trials.
• Surface Optimization: The BioShare lens successfully provided an immediate "smoothing" effect on the irregular corneal topography characteristic of ABMD, restoring optical clarity without invasive surgical intervention.

"Seeing a patient move from legal blindness to 20/70 vision in just three days is a testament to the regenerative potential of the BioShare architecture," said Chris Adams, CEO of Diopter Technologies. "This proof-of-concept result validates our platform strategy and brings us one step closer to providing a non-surgical solution for millions suffering from corneal dystrophies."

About BioShare™

The BioShare device is a breakthrough therapeutic lens utilizing a unique three-layer construction of collagen and amnion. Designed for regenerative medicine and ophthalmology, it serves as a biological bandage that promotes healing while immediately improving visual function by neutralizing surface irregularities.

About Diopter Technologies

Based in Cambridge, MA, Diopter is a biotechnology company dedicated to developing innovative therapies for ocular health and regenerative medicine.

Diopter Technologies, a leader in next-generation ocular therapeutics, is proud to announce the development of its proprietary dissolving amniotic membrane biopolymer contact lens—a transformative solution for the treatment of ocular surface diseases such as dry eye, corneal injuries, and post-surgical healing. This innovation positions Diopter at the forefront of a rapidly expanding global market projected to exceed $5 billion by 2028.

For Investor Inquiries: media@diopterlabs.com diopterlabs.com

This press release contains forward-looking statements regarding Diopter Technologies’ business and technology. Actual results may differ materially due to risks and uncertainties.

Media Contact
Company Name: Diopter Technologies
Contact Person: Christopher Adams
Email: Send Email
Country: United States
Website: http://diopterlabs.com